دورية أكاديمية
Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
| العنوان: | Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns. |
|---|---|
| المؤلفون: | Resende HM; Hospital Hinja, Volta Redonda, Rio de Janeiro, Brazil.; Departamento de Clínica Médica, Centro Universitário UNIFOA, Volta Redonda, Rio de Janeiro, Brazil., Ladislau L; Libbs Farmacêutica, São Paulo, São Paulo, Brazil., Cardoso ACF; Libbs Farmacêutica, São Paulo, São Paulo, Brazil., Brandão JDP; Libbs Farmacêutica, São Paulo, São Paulo, Brazil., Assis BR; Departamento de Clínica Cirúrgica, Centro Universitário UNIFOA, Volta Redonda, Rio de Janeiro, Brazil., Cardoso P; Departamento de Clínica Médica, Centro Universitário UNIFOA, Volta Redonda, Rio de Janeiro, Brazil., Marassi PHA; Departamento de Clínica Médica, Centro Universitário UNIFOA, Volta Redonda, Rio de Janeiro, Brazil., Castilho V; Libbs Farmacêutica, São Paulo, São Paulo, Brazil. |
| المصدر: | JCO global oncology [JCO Glob Oncol] 2021 Aug; Vol. 7, pp. 1316-1324. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101760170 Publication Model: Print Cited Medium: Internet ISSN: 2687-8941 (Electronic) Linking ISSN: 26878941 NLM ISO Abbreviation: JCO Glob Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2020]- |
| مواضيع طبية MeSH: | Biosimilar Pharmaceuticals*/therapeutic use , Breast Neoplasms*/drug therapy , Oncologists*, Brazil ; Female ; Humans ; Trastuzumab/therapeutic use |
| مستخلص: | Purpose: Breast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]). The trastuzumab biosimilar was the first oncology biosimilar approved in Brazil for HER2-positive breast cancer treatment. This study aimed to assess the current level of knowledge of biosimilars, comfort of use, extrapolation indications, and switching of practices among oncologists in Brazil. Methods: A 24-question survey was developed using an online platform that sought information regarding responders' characteristics and use of biosimilars. The survey analyzed the basic knowledge of biosimilars, trastuzumab biosimilars, level of comfort with extrapolation, switching treatment regimens, and opinions concerning the cost of HER2-positive breast cancer therapy. Data were collected between July and September 2019 and included 144 oncologists from five Brazilian regions. Results: In total, 95% of respondents could identify the most appropriate definition of biosimilars and 96% felt comfortable prescribing trastuzumab biosimilars. Although 63% of respondents would use the biosimilar in all settings wherein the reference biologic was approved, 35% would use the biosimilar for cases involving metastatic disease. Although 82% of oncologists were in favor of switching from a reference biologic to a biosimilar, 18% would avoid switching regimens. The lack of studies detailing switching to other regimens and the correct timing to switch was the major concern. The cost of HER2 therapy was a significant concern for most oncologists. Conclusion: Oncologists demonstrated a high level of knowledge of biosimilars and encouraging levels of prescriber use; however, extrapolation and switching treatment regimens are barriers to the effective use of biosimilars in cancer treatment. Efforts should be concentrated on strategies involving medical education programs on biosimilars. Competing Interests: Heloísa M. ResendeConsulting or Advisory Role: Libbs PharmaceuticalSpeakers' Bureau: Libbs PharmaceuticalTravel, Accommodations, Expenses: Pfizer Leandro LadislauEmployment: Daiichi Sankyo/Brazil (current), Libbs Pharmaceutical (previous) Ana Carolina F. CardosoEmployment: Libbs Pharmaceutical Juliana Dinéia P. BrandãoEmployment: Libbs Pharmaceutical Vivienne CastilhoEmployment: Libbs PharmaceuticalNo other potential conflicts of interest were reported. |
| References: | Clin Pharmacol Ther. 2020 Oct;108(4):734-755. (PMID: 32236956) Lancet Oncol. 2016 Jan;17(1):e31-8. (PMID: 26758759) Lancet Haematol. 2018 Nov;5(11):e543-e553. (PMID: 30389036) Sci Rep. 2021 Mar 16;11(1):5956. (PMID: 33727667) Bioanalysis. 2013 Mar;5(5):517-20. (PMID: 23425265) Ann Rheum Dis. 2017 Feb;76(2):355-363. (PMID: 27130908) BMJ Open. 2020 May 5;10(5):e034183. (PMID: 32371511) Ann Rheum Dis. 2018 Feb;77(2):234-240. (PMID: 29042358) Biologicals. 2020 Jan;63:97-100. (PMID: 31836276) ESMO Open. 2019 Mar 6;4(2):e000460. (PMID: 30962961) NDT Plus. 2009 Jan;2(Suppl_1):i27-i36. (PMID: 19461855) Braz J Med Biol Res. 2018 Jan 11;51(3):e7214. (PMID: 29340530) N Engl J Med. 2011 Aug 4;365(5):385-8. (PMID: 21812668) Lancet Oncol. 2018 Jul;19(7):987-998. (PMID: 29880292) Lancet Oncol. 2014 Dec;15(13):e594-e605. (PMID: 25456378) Adv Ther. 2017 Jan;33(12):2160-2172. (PMID: 27798772) Pharmaceuticals (Basel). 2014 Sep 17;7(9):943-53. (PMID: 25232798) JAMA Oncol. 2018 Feb 1;4(2):241-247. (PMID: 28727871) BMJ Open. 2017 Jun 21;7(6):e016730. (PMID: 28637743) Ann Rheum Dis. 2017 Aug 9;:. (PMID: 28794078) Lancet. 2017 Jun 10;389(10086):2304-2316. (PMID: 28502609) Anticancer Res. 2019 Jul;39(7):3971-3973. (PMID: 31262930) Lancet Oncol. 2020 Dec;21(12):e575-e588. (PMID: 33271114) |
| المشرفين على المادة: | 0 (Biosimilar Pharmaceuticals) P188ANX8CK (Trastuzumab) |
| تواريخ الأحداث: | Date Created: 20210820 Date Completed: 20211102 Latest Revision: 20211102 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8457873 |
| DOI: | 10.1200/GO.20.00649 |
| PMID: | 34415791 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2687-8941 |
|---|---|
| DOI: | 10.1200/GO.20.00649 |